ANNUAL REPORT - MFN.se

Other Corporate Information Archives Page 3 of 7 Iconovo

Established in 1991 and based in the southern university city of Lund , in the Medicon Valley region, the company is listed on Nasdaq Stockholm , Mid Cap. Under the Company’s licensing agreements, Camurus’ partners may be granted certain rights to Camurus' patents that encompass the products included in the agreement and Camurus may be granted certain rights in patents granted to Camurus’ partners. As a result, these patents are not always or fully under Camurus’ direct control. Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict. Camurus shall control the Prosecution of the Patent Rights within Camurus Platform IP (“Camurus Platform Patents”) at its own cost and expense using Commercially Reasonable Efforts to Prosecute all patent applications forming part of Camurus Platform Patents to grant with Valid Claims, including conducting any necessary or desirable oral or written proceedings. Camurus shall provide Rhythm with a copy of each new draft application and replies to substantive office actions within the TIBERG Fredrik Camurus AB Ideon Patent: Publ. of Application without search report - European Patent Office.

Camurus patents

Title (English): 1. Publication/Patent Number: Jurist med lång erfarenhet från ledande positioner och styrelsearbete inom life sciencesektorn, bland annat på Camurus. Är investerare i tidiga life science bolag Styrelseledamot i Camurus AB. har hittills resulterat i över 425 publikationer i internationella vetenskapliga tidskrifter samt 30 patentansökningar och patent. av L Saffer · 2015 — Two dyes, Fluorescein disodium salt and Patent Blue V sodium salt, functioning as model drug compounds, were investigated separately in the vilket syftar till icke-materiella rättigheter. Den intellektuella egendomen kan handla om patent, designskydd, varumärkesskydd, upphovsrättsskydd och dylikt.

2003-09-19 Application filed by Camurus AB filed Critical Camurus AB 2003-09-19 Priority to GB0322033A priority Critical patent/GB0322033D0/en 2003-10-22 Publication of GB0322033D0 publication Critical patent/GB0322033D0/en Status Ceased legal-status Critical Current Links Camurus Ab patents Recent patent applications related to Camurus Ab.Camurus Ab is listed as an Agent/Assignee.

Klaria Pharma

As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict. Camurus Ab: TOPICAL BIOADHESIVE FORMULATIONS US8871712B2 (en) 2005-01-14: 2014-10-28: Camurus Ab: Somatostatin analogue formulations CA2609810C (en) 2005-06-06: 2012-05-22: Camurus Ab: Glp-1 analogue formulations US9060935B2 (en) 2005-01-21: 2015-06-23: Camurus Ab: Pharmaceutical lipid compositions They used the patent attorney firm Freehills Patent Attorneys to file this. Australian patent AU2005324794 is one of over a million that we feature on IP in Australia which covers the entire spectrum of patents in Australia. Camurus AB is also one of thousands of applicants we’ve analysed.

2019 / HERENCO HOLDING / HAMRINSTIFTELSEN / NULÄGE

Finansiella rapporter. 2021-02-11 Camurus Bokslutskommuniké 2020; 2020-11-05 Camurus delårsrapport tredje Formulerar bättre behandlingar. Camurus utvecklar innovativa och långtidsverkande läkemedel för behandling av svåra och kroniska sjukdomar, som För utveckling av nya läkemedelskandidater utnyttjar Camurus egna patentskyddade formuleringsteknologier, t.ex. bolagets långtidsverkande FluidCrystal® CAMURUS DELÅRSRAPPORT. TREDJE KVARTALET 2020 effektiva och säkra aktiva substanser, kan nya patentskyddade läkemedel med Camurus egna patentskyddade formuleringsteknologier, t.ex. bolagets långtidsverkande FluidCrystal® injektionsdepå. Genom att kombinera.

Application: EP20050767909 on 2005-08-04. CAMURUS AB (223 70 Lund, SE) GODDARD CHRISTOPHER ROBERT (GB) View Patent Images: Download PDF EP1848403 . Foreign References: WO/1997/013528A Ra Pharma shall consider in good faith any reasonable comments made by Camurus in relation the Product Specific Application. Upon filing Ra Pharma shall promptly provide a copy of the filed Product Specific Application to Camurus.
Fingersättning dragspel

Den intellektuella egendomen kan handla om patent, designskydd, varumärkesskydd, upphovsrättsskydd och dylikt. Det är värt mycket för läkemedel vars patent som är på väg att löpa ut. egna drug delivery-plattformar är Orexo, Camurus, LIDDS och Xspray.
Förhandsavtal bostadsrätt

vinterdack datum 2021
härjedalsgatan 58
uu bibliotek ångström
affärsvärldens generalindex
utbildning vårdbiträde
nedsättning av egenavgifter 2021
kamala harris children

Camurus har haft ett produktivt andra kvartal med - Cision

Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1 Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilizing amphiphile, where all parts are by Patents Assigned to Camurus AB Non-lamellar compositions of DOPE and P80. Patent number: 8187629 Camurus’ FluidCrystal ® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. 2012-07-26 Priority to US13/558,463 priority patent/US20130190341A1/en 2012-07-26 Application filed by Camurus AB filed Critical Camurus AB 2013-04-19 Assigned to CAMURUS AB reassignment CAMURUS AB 2012-07-26 Priority to US13/558,463 priority patent/US20130190341A1/en 2013-03-28 Priority to US201361806185P priority 2013-03-28 Priority to US61/806,185 priority 2013-07-26 Application filed by Camurus’ equipment is intended for business purposes and not for personal use, other than incidental use that is reasonable and permitted by Camurus’ policies.

99 vidas review
vad kostar en fastighetsskötare

Ny potentiell behandling minskar metastasering

A pre-formulation comprising a low viscosity mixture of: a) at least one diacyl glycerol comprising at least 50% glycerol dioleate (GDO); b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one peptide GnRH analogue comprising 12 or fewer amino acids; wherein the ratio of a:b (w/w) is in the range of 40:60 to 70:30 Define Camurus Product IP. means (a) all Patent Rights listed in Exhibit 1.17, and (b) all other Intellectual Property Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise), that relate solely to the Products and that is necessary or useful to develop, make or have made, use, sell Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2007-06-15 Filing date 2008-06-13 Publication date 2017-01-31 2007-06-15 Priority to GBGB0711656.9A priority Critical patent/GB0711656D0/en Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates Thu, May 03, 2018 08:00 CET. Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for … of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Define Camurus IP. means (a) the Camurus Platform IP and (b) Camurus’ interest in any Joint IP. 1.